Clinical trials - Press Releases

Date	Title	Company
11-Oct-2023	Cytovation Reports Promising Interim Results from Phase 1/2a CICILIA Study with CyPep-1 in Solid Tumors	Cytovation ASA
11-Oct-2023	Roche’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions	Roche
11-Oct-2023	Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies	Roche
10-Oct-2023	Valo Therapeutics Announces Acquisition of Bruker Corporation’s Latest Mass Spectrometer Platform for Tumor Antigen Identification with ValoTx’s PeptiCHIP Technology	Valo Therapeutics
10-Oct-2023	GPCR Therapeutics Expands Pipeline into Fibrosis with a Combination Approach Targeting LPA1	GPCR Therapeutics
10-Oct-2023	Mission Therapeutics to Present at Michael J. Fox Foundation’s 15th Annual Parkinson’s Disease Therapeutics Conference	Mission Therapeutics
10-Oct-2023	New guidance launches to enhance quality and improve patient experience in healthcare sector	BSI
10-Oct-2023	Innovative Trials launches ‘first of its kind’ service to boost clinical trial patient recruitment and retention	Innovative Trials
10-Oct-2023	Life sciences leaders unite to condemn radical plans to rewrite medicines scheme	British Pharmaceutical Industry (ABPI)
10-Oct-2023	Novotech Secures Consecutive Frost & Sullivan CRO Company of the Year Award	Novotech
10-Oct-2023	Elsevier launches new PharmaPendium, empowering pharma companies to bring novel drugs to market faster and increase success of regulatory submissions	Elsevier
10-Oct-2023	LYNPARZA (OLAPARIB) ACCEPTED FOR USE IN SCOTLAND AS ADJUVANT TREATMENT FOR PATIENTS WITH GERMLINE BRCA-MUTATED HER2-NEGATIVE HIGH RISK EARLY BREAST CANCER	AstraZeneca
10-Oct-2023	Creative Diagnostics Launches New Azaperone Test Reagents for Research Applications	Creative Diagnostics
10-Oct-2023	Creative Diagnostics Launches Checkerboard Assay Services	Creative Diagnostics
10-Oct-2023	Creative Diagnostics Launches New Anti-Small Molecule Label Antibodies to Facilitate NALFIA Development	Creative Diagnostics
06-Oct-2023	Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America	Moberg Pharma
05-Oct-2023	Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA Phase 2a Clinical Trial	Agomab
05-Oct-2023	Veranova Announces Appointment of New Advisory Board	Veranova
05-Oct-2023	Forxiga met primary endpoint in T2NOW Phase III trial, one of the largest paediatric type 2 diabetes studies performed to date	AstraZeneca
04-Oct-2023	Phastar Net-Zero Target Approved by the Science Based Targets Initiative	Phastar